Comparison of Two Assays to Determine Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis in relation to Other Chronic Inflammatory Rheumatic Diseases: Assaying Anti-Modified Citrullinated Vimentin Antibodies Adds Value to Second-Generation Anti-Citrullinated Cyclic Peptides Testing

Table 4

Utility values of anti-CCP2, anti-MCV, or any of these assays in rheumatoid arthritis in comparison with other chronic inflammatory rheumatic diseases (CIRD).

Utility values of the assays for anti-CCP2 and anti-MCV results	Anti-CCP2	Anti-MCV	Anti-CCP2 or Anti-MCV
Sensitivity % (95% CI)	66 (58–74)	81 (73–87)	85 (78–90)
Specificity % (95% CI)	92 (84–97)	96 (90–99)	92 (84–97)
Positive predictive value % (95% CI)	93 (86–97)	97 (93–99)	94 (89–98)
Negative predictive value % (95% CI)	62 (53–71)	75 (66–83)	79 (70–86)
LR+	8.13 (3.96–16.7)	23.22 (7.62–70.77)	10.47 (5.13–21.36)
LR−	0.37 (0.29–0.47)	0.20 (0.14–0.28)	0.16 (0.11–0.24)
Prevalence	62 (67–89)	62 (68–89)	62 (56–68)

LR+: positive likelihood ratio; LR−: negative likelihood ratio.